Skip to main content
TipRanks
Go Ultimate75% OFF

Nova Leap Health (NLH) AI Stock Analysis

15 Followers
TSE:NLH

Nova Leap Health

(TSXV:NLH)

Select Model
Rating:72Outperform
Price Target:CAD 0.54â–²(15.74% Upside)
Action:reiterated
Date:11/14/26

The score is led by improving financial performance, low leverage, and positive free cash flow. Technical indicators provide moderate support, while the relatively demanding P/E ratio and absent dividend yield constrain the overall score.

Positive Factors
Improving ProfitabilityTTM profitability has recovered after the 2025 loss, while EBIT margin also improved. If maintained, this stronger earnings base can support reinvestment and improve operating resilience, although the evidence reflects a recent recovery rather than a long record of consistency.
Negative Factors
Earnings VolatilityThe return to profit is encouraging, but repeated losses and large historical margin swings show that earnings power has not yet demonstrated consistent durability. This volatility makes future profitability less predictable and could limit confidence in sustained returns over the medium term.

Nova Leap Health (NLH) vs. iShares MSCI Canada ETF (EWC)

-20%0%20%40%60%80%100%TSE:NLH+56.67%EWC+16.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 42.78M
Dividend Yield
―
Average Volume (3M)
14.65K
Price to Earnings (P/E)
24.4
Beta (1Y)
0.32
Revenue Growth
15.57%
EPS Growth
65.83%
Country
Canada
Employees
541
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Nova Leap Health Business Overview & Revenue Model

Company Description

Nova Leap Health Corp. delivers a comprehensive array of in-home and healthcare-at-home solutions across the United States and Canada. Their offerings encompass specialized dementia support, social companionship, assistance with personal needs, and t...

Nova Leap Health Financial Statement Overview

Summary

Financial performance is improving, supported by strong revenue growth, positive net income, low leverage, growing equity, and positive free cash flow. Modest margins, rising debt, and inconsistent historical cash-flow trends limit the score.

Income Statement

72Positive

Balance Sheet

85Very Positive

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue34.58M32.02M25.76M26.18M28.21M21.28M
Gross Profit13.31M11.85M9.89M9.77M9.98M7.21M
EBITDA2.65M1.97M2.50M1.35M420.35K4.76M
Net Income1.23M-193.19K1.38M-1.05M-835.75K1.76M
Balance Sheet
Total Assets25.91M23.44M22.39M20.90M23.95M26.77M
Cash, Cash Equivalents and Short-Term Investments1.93M1.49M1.40M894.76K1.27M1.73M
Total Debt4.39M2.93M2.53M1.40M3.97M6.20M
Total Liabilities6.24M4.43M4.14M2.70M5.27M8.29M
Stockholders Equity19.67M19.01M18.25M18.20M18.68M18.48M
Cash Flow
Free Cash Flow2.30M1.42M1.36M2.13M949.49K2.18M
Operating Cash Flow2.27M1.42M1.39M2.15M1.02M2.18M
Investing Cash Flow-2.26M-1.26M-1.59M-23.13K-56.24K-7.40M
Financing Cash Flow369.09K-86.91K729.78K-2.52M-1.41M4.33M

Nova Leap Health Technical Analysis

Technical Analysis SentimentNegative
Last Price0.47

Price Trends

50DMA0.49Negative
100DMA0.48Negative
200DMA0.41Positive

Market Momentum

MACD0.00Negative
RSI46.94Neutral
STOCH73.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.49, and above the 200-day MA of 0.41, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 46.94 is Neutral, neither overbought nor oversold. The STOCH value of 73.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NLH.

Nova Leap Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TSE:NLH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:DRTSE:DR72OutperformCAD 276.56M8.6344.01%2.11%4.53%-55.43%
TSE:NLHTSE:NLH72OutperformCAD 41.30M24.356.40%―15.57%65.83%
TSE:SIATSE:SIA70OutperformCAD 2.27B40.445.98%4.58%14.90%13.31%
TSE:EXETSE:EXE67NeutralCAD 2.77B20.6832.84%1.79%36.24%29.85%
TSE:CRRXTSE:CRRX63NeutralCAD 201.00M7.7923.35%2.58%3.42%40560.00%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%25%50%75%100%TSE:NLHTSE:CRRXTSE:EXETSE:SIATSE:DRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:NLH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:NLHNova Leap Health0.470.1967.86%
TSE:CRRXCarerx Corporation3.21-0.10-3.05%
TSE:EXEExtendicare Inc.28.819.2547.26%
TSE:SIASienna Senior Living20.461.186.12%
TSE:DRMedical Facilities Corp17.433.4724.89%

Nova Leap Health Corporate Events

Business Operations and StrategyFinancial Disclosures

Nova Leap to Spotlight Record Quarter and Growth Strategy at Planet MicroCap Showcase

Positive
Oct 14, 2026

Nova Leap Health Corp. will showcase its record second-quarter performance and growth strategy at the Planet MicroCap Showcase in Toronto later this month. President and CEO Chris Dobbin is scheduled to deliver a webcast presentation on October 28, f...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026